After melanoma surgery, Bristol’s Opdivo offers new care standard

MADRID, Sept 11 (Reuters) – Bristol-Myers Squibb’simmunotherapy drug Opdivo is a better and safer option than itsolder medicine Yervoy for treating melanoma patients who havehad surgery to remove disease, researchers reported on Monday.
The post After melanoma surgery, Bristol’s Opdivo offers new care standard appeared first on RocketNews | Top News Stories From Around the Globe.